Benefits of Tiotropium + Olodaterol Over Tiotropium at Delaying Clinically Significant Events in Patients with COPD Classified as GOLD B
Rattachement africain : de, gb, us, au, ca. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Rationale: This post hoc analysis of the TONADO® 1 + 2 data investigated whether tiotropium (t) + olodaterol (o) is more effective than t at delaying clinically significant events in patients with GOLD stage B COPD (symptomatic COPD and l low risk of exacerbations). These included time to first clinically important deterioration in trough forced expiratory volume in 1 second (FEV1) or St. George's Respiratory Questionnaire (SGRQ) score, severe exacerbation, and death. Methods: 5162 patients were randomized to o 5 µg, t 2.5 µg, t 5 µg, t/o 2.5/5 µg, or t/o 5/5 µg (delivered via Respimat® inhaler) in two 52-week, parallel-group, double-blind studies (TONADO® 1 [NCT01431274] and TONADO® 2 [NCT01431287]). In this post hoc analysis of the combined TONADO® data, clinical deterioration was defined according to a composite end point: time to first decrease in trough FEV1 from baseline of >/= 100 ml; increase in SGRQ total score from baseline of >/= 4 units; severe (hospitalized) exacerbation; or death. The time to first occurrence of one of these events was recorded as the time to clinical deterioration. Only patients classified as GOLD B were included. Results: 306 and 310 patients were included in this analysis in the t 5 µg and t+o 5/5 µg treatment groups, respectively. Time to clinical deterioration was significantly longer with t+o 5/5 µg than t 5 µg (25th percentile 128 versus 85 days; hazard ratio 0.650; 95% CI 0.524, 0.805; p < 0.0001). Times to trough FEV1 decline and SGRQ increase were significantly longer with t+o 5/5 µg than t 5 µg (226 versus 91 days and 369 versus 175 days, respectively). 25th percentiles for time to severe exacerbation and time to death were not estimable due to low event rates. Conclusions: T+o increased time to clinical deterioration compared to t alone in patients with GOLD stage B disease. This suggests that in this patient population t+o is more effective than t in preventing these significant events. Content already presented at ATS congress 2016
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Benefits of Tiotropium + Olodaterol Over Tiotropium at Delaying Clinically Significant Events in Patients with COPD Classified as GOLD B
- Date Crossref
- 23/02/2017
- Éditeur
- Georg Thieme Verlag KG
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Les institutions déclarées
Une affiliation ne permet pas de déduire la nationalité d’un auteur.